Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 7
Submit an article Journal homepage
639
Views
95
CrossRef citations to date
0
Altmetric
Special Focus: Vaccine Adjuvants - Review

Influenza virosomes as vaccine adjuvant and carrier system

Christian Moser Pevion Biotech AG, Worblentalstrasse 32, Ittigen CH-3063, Switzerland. [email protected]; Pevion Biotech AG, Worblentalstrasse 32, Ittigen CH-3063, Switzerland. [email protected]
,
Matthias Müller Pevion Biotech AG, Worblentalstrasse 32, Ittigen CH-3063, Switzerland; Pevion Biotech AG, Worblentalstrasse 32, Ittigen CH-3063, Switzerland
,
Matthias D Kaeser Pevion Biotech AG, Worblentalstrasse 32, Ittigen CH-3063, Switzerland; Pevion Biotech AG, Worblentalstrasse 32, Ittigen CH-3063, Switzerland
,
Ulrike Weydemann IP Services, Unter Linden 35, Köln D-50859, Germany; IP Services, Unter Linden 35, Köln D-50859, Germany
&
Mario Amacker Pevion Biotech AG, Worblentalstrasse 32, Ittigen CH-3063, Switzerland; Pevion Biotech AG, Worblentalstrasse 32, Ittigen CH-3063, Switzerland
Pages 779-791 | Published online: 09 Jan 2014

References

  • Almeida JD, Edwards DC, Brand CM, Heath TD. Formation of virosomes from influenza subunits and liposomes. Lancet 2(7941), 899–901 (1975).
  • Morein B, Helenius A, Simons K, Pettersson R, Kääriäinen L, Schirrmacher V. Effective subunit vaccines against an enveloped animal virus. Nature 276(5689), 715–718 (1978).
  • Johnson JE, Chiu W. Structures of virus and virus-like particles. Curr. Opin. Struct. Biol. 10(2), 229–235 (2000).
  • Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol. Chem. 389(5), 521–536 (2008).
  • Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. Methods 40(1), 60–65 (2006).
  • Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10(11), 787–796 (2010).
  • Buonaguro F, Buonaguro L. The application of virus-like particles to human diseases. Expert Rev. Vaccines 12(2), 99 (2013).
  • Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev. Vaccines 10(11), 1569–1583 (2011).
  • Kaneda Y. Virosome: a novel vector to enable multi-modal strategies for cancer therapy. Adv. Drug Deliv. Rev. 64(8), 730–738 (2012).
  • Waelti E, Wegmann N, Schwaninger R et al. Targeting her-2/neu with antirat Neu virosomes for cancer therapy. Cancer Res. 62(2), 437–444 (2002).
  • Felnerova D, Viret JF, Glück R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 15(6), 518–529 (2004).
  • Waelti ER, Glück R. Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int. J. Cancer 77(5), 728–733 (1998).
  • Schoen P, Chonn A, Cullis PR, Wilschut J, Scherrer P. Gene transfer mediated by fusion protein hemagglutinin reconstituted in cationic lipid vesicles. Gene Ther. 6(5), 823–832 (1999).
  • Cusi MG, Gluck R. Potential of DNA vaccines delivered by influenza virosomes. Vaccine 18(15), 1435 (2000).
  • Cusi MG, Terrosi C, Savellini GG, Di Genova G, Zurbriggen R, Correale P. Efficient delivery of DNA to dendritic cells mediated by influenza virosomes. Vaccine 22(5–6), 735–739 (2004).
  • de Jonge J, Holtrop M, Wilschut J, Huckriede A. Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther. 13(5), 400–411 (2006).
  • de Jonge J, Leenhouts JM, Holtrop M et al. Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. Biochem. J. 405(1), 41–49 (2007).
  • Huckriede A, De Jonge J, Holtrop M, Wilschut J. Cellular delivery of siRNA mediated by fusion-active virosomes. J. Liposome Res. 17(1), 39–47 (2007).
  • Lund PE, Hunt RC, Gottesman MM, Kimchi-Sarfaty C. Pseudovirions as vehicles for the delivery of siRNA. Pharm. Res. 27(3), 400–420 (2010).
  • Jamali A, Holtrop M, de Haan A et al. Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination. Immunol. Lett. 148(1), 77–82 (2012).
  • Stegmann T, Morselt HW, Booy FP, van Breemen JF, Scherphof G, Wilschut J. Functional reconstitution of influenza virus envelopes. EMBO J. 6(9), 2651–2659 (1987).
  • Glück R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ Jr. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 90(6), 2491–2495 (1992).
  • Mischler R, Metcalfe IC. Inflexal V a trivalent virosome subunit influenza vaccine: production. Vaccine 20(Suppl. 5), B17–B23 (2002).
  • Glück R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 344(8916), 160–163 (1994).
  • Conne P, Gauthey L, Vernet P et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 15(15), 1675–1679 (1997).
  • Herzog C, Hartmann K, Künzi V et al. Eleven years of Inflexal V – a virosomal adjuvanted influenza vaccine. Vaccine 27(33), 4381–4387 (2009).
  • Bovier PA. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev. Vaccines 7(8), 1141–1150 (2008).
  • Glück R. Intranasal immunization against influenza. J. Aerosol Med. 15(2), 221–228 (2002).
  • Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N. Engl. J. Med. 350(9), 896–903 (2004).
  • Zurbriggen R, Novak-Hofer I, Seelig A, Glück R. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog. Lipid Res. 39(1), 3–18 (2000).
  • Zurbriggen R. Immunostimulating reconstituted influenza virosomes. Vaccine 21(9–10), 921–924 (2003).
  • Huckriede A, Bungener L, Stegmann T et al. The virosome concept for influenza vaccines. Vaccine 23(Suppl. 1), S26–S38 (2005).
  • Moser C, Amacker M, Zurbriggen R. Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev. Vaccines 10(4), 437–446 (2011).
  • Zurbriggen R, Glück R. Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine 17(11–12), 1301–1305 (1999).
  • Amacker M, Moese S, Kammer AR, Helenius A, Zurbriggen R. Influenza virosomes as delivery systems for antigens. In: Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids, and Vaccines. Jorgensen L, Nielsen HM (Eds). John Wiley & Sons Ltd, West Sussex, UK, 377–393 (2009).
  • De Bernardis F, Amacker M, Arancia S et al. A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine 30(30), 4490–4498 (2012).
  • Amacker M, Engler O, Kammer AR et al. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int. Immunol. 17(6), 695–704 (2005).
  • Kammer AR, Amacker M, Rasi S et al. A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses. Vaccine 25(41), 7065–7074 (2007).
  • Bungener L, Serre K, Bijl L et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20(17–18), 2287–2295 (2002).
  • Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 23(10), 1232–1241 (2005).
  • Künzi V, Dornseiff M, Horwath J, Hartmann K. Safe vaccination of children with a virosomal adjuvanted influenza vaccine. Vaccine 27(8), 1261–1265 (2009).
  • Frösner G, Steffen R, Herzog C. Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration. J. Travel Med. 16(6), 413–419 (2009).
  • Wang BZ, Xu R, Quan FS, Kang SM, Wang L, Compans RW. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS ONE 5(11), e13972 (2010).
  • Pedersen GK, Ebensen T, Gjeraker IH et al. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS ONE 6(11), e26973 (2011).
  • Mallick AI, Parvizi P, Read LR, Nagy E, Behboudi S, Sharif S. Enhancement of immunogenicity of a virosome-based avian influenza vaccine in chickens by incorporating CpG-ODN. Vaccine 29(8), 1657–1665 (2011).
  • Mallick AI, Kulkarni RR, St Paul M et al. Vaccination with CpG-adjuvanted avian influenza virosomes promotes antiviral immune responses and reduces virus shedding in chickens. Viral Immunol. 25(3), 226–231 (2012).
  • Radosevic K, Rodriguez A, Mintardjo R et al. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants. Vaccine 26(29–30), 3640–3646 (2008).
  • Cox RJ, Pedersen G, Madhun AS et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 29(45), 8049–8059 (2011).
  • Leroux-Roels G, Maes C, Clement F et al. Randomized phase i: safety, immunogenicity and mucosal antiviral activity in young healthy women vaccinated with HIV-1 Gp41 P1 peptide on virosomes. PLoS ONE 8(2), e55438 (2013).
  • Bomsel M, Tudor D, Drillet AS et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34(2), 269–280 (2011).
  • Vacher G, Gremion C, Moser C, Stoffel SA, Amacker M, Zurbriggen R, Gurny R, Borchard G. Virosomal C. albicans vaccine for vaginal application: formulation development and toxicity/immunogenicity studies. J. Drug Del. Sci. Tech. 22(5), 447–452 (2012).
  • de Jonge J, Amorij JP, Hinrichs WL, Wilschut J, Huckriede A, Frijlink HW. Inulin sugar glasses preserve the structural integrity and biological activity of influenza virosomes during freeze-drying and storage. Eur. J. Pharm. Sci. 32(1), 33–44 (2007).
  • Angel J, Chaperot L, Molens JP et al. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells. Vaccine 25(19), 3913–3921 (2007).
  • Schumacher R, Adamina M, Zurbriggen R et al. Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation. Vaccine 22(5–6), 714–723 (2004).
  • Van Der Wielen M, Vertruyen A, Froesner G et al. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1–16 years. Pediatr. Infect. Dis. J. 26(8), 705–710 (2007).
  • Peduzzi E, Westerfeld N, Zurbriggen R, Pluschke G, Daubenberger CA. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial. Clin. Immunol. 127(2), 188–197 (2008).
  • Genton B, Pluschke G, Degen L et al. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS ONE 2(10), e1018 (2007).
  • Thompson FM, Porter DW, Okitsu SL et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS ONE 3(1), e1493 (2008).
  • Cech PG, Aebi T, Abdallah MS et al. Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized Phase 1b trial in semi-immune adults & children. PLoS ONE 6(7), e22273 (2011).
  • Wiedermann U, Wiltschke C, Jasinska J et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res. Treat. 119(3), 673–683 (2010).
  • Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15(11), 1209–1213 (1997).
  • Bovier PA. Recent advances with a virosomal hepatitis A vaccine. Expert Opin. Biol. Ther. 8(8), 1177–1185 (2008).
  • Abarca K, Ibáñez I, de la Fuente P et al. Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1–16 years. Vaccine 29(48), 8855–8862 (2011).
  • Glück R, Wälti E. Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV). Dev. Biol. (Basel) 103, 189–197 (2000).
  • Hatz C, van der Ploeg R, Beck BR, Frösner G, Hunt M, Herzog C. Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years. Clin. Vaccine Immunol. 18(5), 885–887 (2011).
  • Lewis DJ, Huo Z, Barnett S et al. Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 4(9), e6999 (2009).
  • de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 26(1), 119–127 (2007).
  • de Bruijn IA, Nauta J, Gerez L, Palache AM. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res. 103(1–2), 139–145 (2004).
  • de Bruijn IA, Nauta J, Gerez L, Palache AM. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects. Vaccine 24(44–46), 6629–6631 (2006).
  • Okitsu SL, Silvie O, Westerfeld N et al. A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS ONE 2(12), e1278 (2007).
  • Tamborrini M, Stoffel SA, Westerfeld N et al. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malar. J. 10, 359 (2011).
  • Hunziker IP, Zurbriggen R, Glueck R et al. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol. 38(6), 475–484 (2001).
  • Murphy CG, Fornier M. HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston Park, N.Y.) 24(5), 410–415 (2010).
  • Wiedermann U, Davis AB, Zielinski CC. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. Breast Cancer Res. Treat. 138(1), 1–12 (2013).
  • Tudor D, Derrien M, Diomede L et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2(5), 412–426 (2009).
  • Sandini S, La Valle R, Deaglio S, Malavasi F, Cassone A, De Bernardis F. A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine. FEMS Immunol. Med. Microbiol. 62(2), 215–224 (2011).
  • Cassone A. Candida vaccines: progress and challenges. Presented at: 11th ASM Conference on Candida and Candidiasis. San Francisco, CA, USA, 1 April 2012.
  • Amacker M. Managing Change from Bench to CTM Production. Presented at: The Immunotherapeutics and Vaccine Summit. Cambridge, MA, USA, 18 August 2012.
  • Moser C, Amacker M, Kammer AR, Rasi S, Westerfeld N, Zurbriggen R. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev. Vaccines 6(5), 711–721 (2007).
  • Khoshnejad M, Young PR, Toth I, Minchin RF. Modified influenza virosomes: recent advances and potential in gene delivery. Curr. Med. Chem. 14(29), 3152–3156 (2007).
  • Daemen T, de Mare A, Bungener L, de Jonge J, Huckriede A, Wilschut J. Virosomes for antigen and DNA delivery. Adv. Drug Deliv. Rev. 57(3), 451–463 (2005).
  • Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS ONE 7(5), e36812 (2012).
  • Influenza vaccine (surface antigen, inactivated, virosome). European Pharmacopoeia 7.8 793–795 (2013).
  • Hepatitis A vaccine (inactivated, virosome). European Pharmacopoeia 7.8, 781–784 (2013).
  • Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38(5), 1404–1413 (2008).
  • Kaeser MD. Manufacturing and QC of virosomal vaccines. Presented at: Virus-like Particle & Nano-particle Vaccines VLPNPV. Cannes, France, 29 November 2012.
  • Holzer BR, Hatz C, Schmidt-Sissolak D, Glück R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 14(10), 982–986 (1996).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.